Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 22; no. 4; pp. e251 - e258
• Main Authors: Brand, B., Gruppo, R., Wynn, T. T., Griskevicius, L., Lopez Fernandez, M. F., Chapman, M., Dvorak, T., Pavlova, B. G., Abbuehl, B. E.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.07.2016
• Subjects: Adult; Antibodies, Neutralizing - blood; Coagulants - chemistry; Coagulants - pharmacokinetics; Coagulants - therapeutic use; extended half-life; Factor VIII - genetics; Factor VIII - metabolism; Factor VIII - therapeutic use; haemophilia A; Half-Life; Hemophilia A - blood; Hemophilia A - drug therapy; Hemorrhage - prevention & control; Hemostasis; Humans; Male; Middle Aged; pegylated recombinant factor VIII; Perioperative Care; perioperative haemostasis; Polyethylene Glycols - chemistry; Recombinant Proteins - biosynthesis; Recombinant Proteins - chemistry; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - therapeutic use; Surgical Procedures, Operative; Treatment Outcome; Young Adult; pegylated recombinant factor VIII; haemophilia A; extended half-life; perioperative haemostasis

Introduction BAX 855 is a pegylated full‐length recombinant factor VIII (rFVIII) with an extended half‐life, built on a licensed rFVIII (ADVATE®). BAX 855 demonstrated efficacy and safety in prophylaxis and the treatment of bleeding episodes in previously treated patients (PTPs) with severe haemophi...